Trial Profile
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms NIAGARA
- Sponsors AstraZeneca
- 13 Jun 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2025.
- 10 Sep 2021 Planned primary completion date changed from 1 Aug 2023 to 30 Jun 2023.
- 10 Sep 2021 Status changed from recruiting to active, no longer recruiting.